Research and development daily Sanofi/Regenerative Dupixent Treatment EoE has been recognized by the FDA as a breakthrough therapy

2020.09.15 Research and Development NEWS: Shorten patient recovery time JAK inhibitors/Redsivir combination therapy up to Phase 3 clinical endpoint; Haussen "Amedini" Neo-Adaptive Initiation Phase III Clinical for NSCLC perioperative therapy; Johnson and Johnson EGFR-MET dual resistance and third generation EGFR-TKI combination therapy approved 4 clinical ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) "Drug Development" Shorten Patient Recovery Time JAK Inhibitor/Redsyvir Combination Therapy Phase 3 Clinical Endpoint Lilly and Incyte announced today that its JAK inhibitor Baricitinib, in combination with Redsivir, reached the main endpoint of the trial in adaptive Phase 3 clinical trial ACT-2 sponsored by the National Institute of Allergy and Infectious Diseases.
compared to Redsiweiser, baricitinib and Redsiweiser can shorten patient recovery time.
Novarma's next-generation anti-VEGF ophthalmology drug reached the critical endpoint of phase 3 research on the 14th, Novarma announced the results of a new generation of anti-VEGF ophthalmology drug Beovu (brolucizumab, also known as RTH258) to treat patients with diabetic macular edema (DME).
study showed that the trial reached the primary and critical secondary endpoints, and that Beovu achieved non-poor results compared to controlled drugs in the average change in optimal corrective vision (BCVA) in year 1 (week 52).
Hausen "Amedini" new adaptive initiation Phase III clinical for NSCLC perioperative treatment 15, Haussen "Amethystini tablets" launched a Phase III clinical, adaptive a combination chemotherapy for non-small cell lung cancer perioperative treatment.
Junshi PD-1 started a Phase III clinical first-line treatment of urethra skin cancer 15, Junshi biotreatment Ripley monoantigen initiated a Phase III clinical, combined standard chemotherapy first-line treatment of local late stage or metastatic urethra skin cancer.
Drug Approval: Sanofi/Regenerative Dupixent Treatment EoE was recognized by the FDA Breakthrough Therapy on the 14th, the FDA has awarded Sanofi/Regenerative Dupixent (dupilumab, Dupilumab) breakthrough treatment designation for the treatment of patients aged 12 years and older with eosinophilic esophitis (EoE).
Johnson and Johnson EGFR-MET dual anti-and third-generation EGFR-TKI combination therapy approved in China 4 clinical CDE publicity, Johnson and Johnson's EGFR-MET dual anti-drug amivantamab injection and third generation EGFR-TKI drug lazertinib tablets of the combination therapy obtained 4 clinical trials implied license, adaptive disorders are: for the treatment of EGFR 19 exons missing or L858R NSCLC patients who activate mutations and develop disease progression after first- or second-line treatment with first- or second-generation TKI;
Hengrui PD-L1/TGF-β dual anti-lung cancer, pancreatic cancer adaptation was approved for clinical 15th, Hengrui targeted PD-L1/TGF-β dual anti-SHR-1701 two new adaptations were approved clinically, respectively, Phase III NSCLC and first-line advanced/metastatic pancreatic cancer.
's bio-dual immunoassist inhibitors were approved for clinical approval in the United States today, and ShoreMay Bio announced that its clinical application for the new EMB-02 drug has been confirmed by the FDA's "Clinical Research Can Start."
According to the press release, EMB-02, which targets both the immunochesin protein PD-1 and LAG-3, is the second self-developed new dual-specific antibody candidate for solid tumor therapy.
the FDA rejected Mallinckrodt's kidney failure drug, the FDA rejected Mallinckrodt's application for Terlipressin to treat rare, aggressive renal failure.
FDA believes more information is needed to support the benefits of Terrigatin over risk in HRS-1 patients.
Baiji Shenzhou / Amgen CD3 / Muc17 double resistance was approved to conduct clinical trials in China on the 15th, Anjin / Baiji Shenzhou Class 1 new drug AMG 199 in China approved clinically, intended for the treatment of MUC17 positive gastric cancer or gastroesophageal junction (G/GEJ) cancer.
assassin Pharmaceuticals 3rd product harvest FDA orphan drug qualification 14, Aachen Pharmaceuticals announced that the United States FDA awarded its own research and development of the original innovative drug APG-115 orphan drug qualification, used in the treatment of stomach cancer.
this is the first time that APG-115 has been granted orphan drug qualification by the FDA, and it is the third drug that Aachen Pharmaceuticals has been qualified as an FDA orphan drug.
first innovative drug ALMB-0168 was approved for clinical 15th, Shi Pharmaceutical Group subsidiary Shanghai Enlemai in the research of new drug ALMB-0168 by CDE clinical implied license, intended for osteosarcoma and tumor bone metastasis adaptation.
pharmaceutical Celexib capsules will soon be approved recently, NMPA official website data show that Qilu pharmaceutical Celesib capsules 4 imitation market applications into the "in the approval" stage.
Collen Pharmaceuticals Fuma acid dioxin tablets will soon be approved recently, NMPA official website data show that Colum Pharmaceuticals Fumarate novotalfide tablets 4 imitation listing applications into the "in the approval" stage.
Sansheng Pharmaceuticals announced that the Beval Pearl Single Anti-Biosimilar Drug China IND was accepted on the 14th, Sansheng Pharmaceuticals announced that the IND application of the Beval Pearl Single Anti-Biosimilar Drug SB8 has been accepted by the State Drug Administration.
research and development partnership to create an innovative ADC Mercer East and Seattle Genetics today, Seattle Genetics and Mercedon jointly announced that they have reached two strategic oncology partnerships.
, the two companies will jointly develop and promote antibody-coupled drugs (ADC) ladiratuzumab vedotin targeting LIV-1 worldwide.